Sindrom Stevens-Johnson (SSJ) melebihi Nekrolisis Epidermal Toksik (NET) pada Geriatri: Laporan kasus

Aliezsa Esthi Kusuma; Dwi Indria Angraini

doi:10.53089/medula.v10i2.82

Authors

Aliezsa Esthi Kusuma
Dwi Indria Angraini

DOI:

https://doi.org/10.53089/medula.v10i2.82

Keywords:

Geriatric, stevens-johnson syndrome, toxic epidermal necrolysis

Abstract

Steven Johnson Syndrome (SSJ) is an acute, life-threatening disease characterized by necrosis and epidermal release in vesicobulosa skin, mucous orifice, and eyes, with severe general symptoms. The incidence of SSJ overlapping Toxic Epidermal Necrolysis (NET) is 1-10 cases per 1 million cases per year. The most common cause is hypersensitivity reactions to drugs. Pathogenesis of SSJ and NET is still not widely known. Symptoms begin with symptoms of prodromal flu like symptoms followed by bullae and epidermolysis. SSJ and NET based on age have been reported not only as risk factors but also associated with increased mortality. A 66-year-old woman presents with rashes, blisters and blisters accompanied by peeling all over her body including the skin, eyes, lips and genitals. Six days before hospital admission the patient had a history of treatment at a first-level health facility in the form of ondansentron, paracetamol, dexamethasone, chlorpheniramine, glyceryl guaiacolate, salbutamol, antacids and ranitidine. On physical examination found about 27% epidermiolisis body with positive sign Nicolsky. SCORTEN calculated on patient 3. Pharmacological treatment given to patients in the form of intravenous and topical antibiotics and steroids.

References

Sah R, Neupane S, Khadka S, Poudyal S, Paneru HR, Sah R, et al. A Case Study of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis (SJS-TEN) Overlap in Mycoplasma pneumoniae-Associated Tracheobronchitis. Case Rep Infect Dis. 2019 May 30;2019:5471765.

Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention. Am J Med. 2016;129(11):1221–5.

Putri ND, Mutiara H, Hasudungan, Sibero HT, Sukohar A. Steven-Johnson Syndrom et causa Paracetamol. J Medula Unila. 2016;6(1):101–7.

Liotti L, Caimmi S, Bottau P, Bernardini R, Cardinale F, Saretta F, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019 Jan 29;90(3-S):52–60.

Oakley AM, Krishnamurthy K. Stevens Johnson Syndrome (Toxic Epidermal Necrolysis). Treasure Island (FL): StatPearls Publishing; 2020. 1.

Dewi CC. Tinjauan atas Stevens-Johnson Syndrome dan Toxic Epidermal Necrolysis. CDK Ed Suplemen-2. 2019;46:55–9.

Chester H, Jariwala S. A case of Stevens-Johnson syndrome with thrombocytopenia. Ann Allergy, Asthma Immunol. 2016;117(5):S19.

Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, et al. Incidence of stevens-johnson syndrome and toxic epidermal necrolysis: A nationwide population-based study using national health insurance database in Korea. PLoS One. 2016;11(11):1–12.

Malik MN, Ullah AM, Ahmad ME, Riaz R, Syed TIS. Pancytopenia in a Patient with Stevens-Johnson Syndrome: A Case Report with Literature Review. Cureus. 2019;11(5):5–11.

Sudarsa PSS, Puspawati NMD, Purnami NKR, Sanjaya IGPH, Hamid ARRH. Toxic Epidermal Necrolysis (TEN) in an elderly with comorbidities : A case report. Bali Med J. 2020;9(1):323–6.

Cohen V. Toxic Epidermal Necrolysis (TEN) [Internet]. Medscape. 2018 [diakses tanggal 6 Juni 2020]. 1. Tersedia di: https://emedicine.medscape.com/article/229698-overview#a7

Purnamawati S, Febriana SA, Danarti R, Saefudin T. Topical treatment for Stevens - Johnson syndrome and toxic epidermal necrolysis: a review. Bali Med J. 2016;5(1):82–90.

Wong A, Malvestiti AA, Hafner M de FS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review. Rev Assoc Med Bras. 2016;62(5):468–73.

Saraogi PP, Nayak CS, Pereira RR, Dhurat RS. Inadvertent Provocative Oral Ondansetron use Leading to Toxic Epidermal Necrolysis in an HIV-infected Patient. Indian J Dermatol. 2012 Nov;57(6):503.

Rajput R, Sagari S, Durgavanshi A, Kanwar A. Paracetamol induced Steven-Johnson syndrome: A rare case report. Contemp Clin Dent. 2015 Sep;6(Suppl 1):S278-81.

Russom M, Debesai M, Zeregabr M, Tesfai F, Abrham G. Toxic Epidermal Necrolysis, Stevens - Johnson syndrome and Erythema Multiform associated with Chlorpheniramine. J Pharmacovigil Pharmacother. 2017;114:1–10.

Maggini V, Lombardi N, Lenti MC, Masi S, Trapani S, Pugi A, et al. A case of pediatric Steven-Johnson Syndrome associated with albuterol consumption. Int Immunopharmacol. 2015 Jul;27(1):154–5.

Shariff A, Hillerson D, Ross J, Ayala-pena E. Stevens-Johnson Syndrome Secondary to Isolated Albuterol Use. CUTIS. 2017;100(2):E6-8.

Auyeung J, Lee M. Successful Treatment of Stevens – Johnson Syndrome with Cyclosporine and Corticosteroid. CJHP. 2018;71(4):272–5.

Kumar R, Das A, Das S. Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines! Indian J Dermatol. 2018;63(2):117–24.

Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5(1):39.

Lihite RJ, Lahkar M, Borah A, Hazarika D, Singh S. A study on drug induced Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and SJS-TEN overlap in a tertiary care hospital of Northeast India. J Young Pharm. 2016;8(2):149–53.

Pease DR. Increased mortality in elderly patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2019;81(4):AB226.

Mockenhaupt M, Roujeau J. Epidermal Necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis). In: Fitzpatrick’s Dermatology. New York: McGraw-Hill; 2019. p. 733–48.

Le H-G, Saeed H, Mantagos IS, Mitchell CM, Goverman J, Chodosh J. Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: A survey. Burns. 2016 Jun;42(4):830–5.

Saka B, Akakpo AS, Teclessou JN, Mahamadou G, Mouhari-Toure A, Dzidzinyo K, et al. Ocular and Mucocutaneous Sequelae among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Togo. Dermatol Res Pract. 2019;2019:4917024.

Seccombe EL, Ardern-Jones M, Walker W, Austin S, Taibjee S, Williams S, et al. Bronchiolitis obliterans as a long-term sequela of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Clin Exp Dermatol. 2019 Dec;44(8):897–902.

Rahmawati YW, Indramaya DM. Studi Retrospektif: Sindrom Stevens-Johnson dan Nekrolisis Epidermal Toksik. Period Dermatology Venereol. 2016;28(2):68–76.

Ba DYH, Brieva J, Silverberg NB, Ms ASP, Mph JIS. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Dermatology. 2017;76(5):811–7.

Jorge J, Kowal-vern A, Fung HCH, Poulakidas SJ. Toxic Epidermal Necrolysis and Graft versus Host Disease after Hematopoietic and Liver Transplantation : A Review. Int J Clin Expl Dermatol. 2018;3(1):1–9.

Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JKG, et al. U.K. guidelines for the management of Stevens – Johnson syndrome/ toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174:1194–227.

Orime M. Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions. J Immunol Res. 2017/10/31. 2017;2017:6928363.

Lerch M, Mainetti C, Beretta-piccoli BT, Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allerg Immunol. 2017;54(1):147–76.

Chan L, Cook DK. A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016. Int J Dermatol. 2019 Oct;58(10):1141–7.

Tseng SCG. Acute management of Stevens-Johnson syndrome and toxic epidermal necrolysis to minimize ocular sequelae. Am J Ophthalmol. 2009 Jun;147(6):949–51.

Michaels B. The role of systemic corticosteroid therapy in erythema multiforme major and stevens-johnson syndrome: a review of past and current opinions. J Clin Aesthet Dermatol. 2009 Mar;2(3):51–5.

Wolff K, Johnson RA. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. New York: McGraw-Hill Companies, Inc; 2018. 1–2000.

Stern RS, Divito SJ. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done. J Invest Dermatol. 2017 May;137(5):1004–8.

Ang C, Tay Y. Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens – Johnson syndrome and toxic epidermal necrolysis. Int J Dermatol. 2011;50:1570–8.

Fan Z-D, Qian X-Q, Yu H-G. Pancytopenia as an early indicator for Stevens-Johnson syndrome complicated with hemophagocytic lymphohistiocytosis: a case report. BMC Pediatr. 2014 Feb;14:38.